# A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage

> **NCT01661140** · PHASE4 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 427 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Methotrexate (stable dose)
- **DRUG:** Tocilizumab
- **DRUG:** Methotrexate (tapering dose)

## Key facts

- **NCT ID:** NCT01661140
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-09
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 427 (ACTUAL)
- **Last updated:** 2016-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01661140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01661140, "A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT01661140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*